EGFR and neoplasm: A study led by Akbay and colleagues revealed that activation of the EGFR pathway resulted in PD-L1 upregulation along with an immunosuppressive tumor microenvironment (TME) characterized by a lower CD8+/CD4+ and CD8+/FOXP3+ tumor-infiltrating lymphocytes (TILs) ratio in a mouse model, and a blockade with PD-1 antibody improved survival [7].